Absci
ABSI | NASDAQ
$7.47
-$0.98 (-11.60%)
At close: Nov 16, 2026, 4:00 PM ET
$7.55
+$0.08 (+1.12%)
After-hours:
Nov 16, 2026, 7:58 PM ET
Absci Company Profile
Company profile explainedCompany Profile
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President & Director |
| Shelby Walker | Chief Legal Officer |
| Zachariah Jonasson | Chief Business Officer & Chief Financial Officer |
| Alexander Khan | CVP of Finance & Head of Investor Relations |
| Christine Lemke | Senior Vice President of Portfolio & Growth Strategy |
| Jeanne Schreuder SPHR | Senior Vice President of People & Experience |
| Moetaz Albizem | Senior Vice President of Clinical Operations |
| Ransi Somaratne FACC | Chief Medical Officer |
| Todd Bedrick | Senior Vice President & Chief Accounting Officer |
| Wen Sha | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 4 | Filing |
| Aug 07, 2026 | 3 | Filing |
Absci
| Country | United States |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 140 |
| CEO | Sean McClain |
Contact Details
18105 SE Mill Plain Boulevard Vancouver,
Washington 98683 United States
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| SIC Code | 8731 |
Recent News
- 4 days ago / seekingalpha.comAbsci Corporation (ABSI) Q3 2026 Earnings Call Transcript
- 4 days ago / marketbeat.comAbsci Q3 Earnings Call Highlights
- 4 days ago / zacks.comAbsci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
- 4 days ago / globenewswire.comAbsci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
- 4 days ago / globenewswire.comAbsci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
- 5 days ago / seekingalpha.comAbsci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
- 21 days ago / globenewswire.comAbsci to Participate in Upcoming Investor Conferences
- 1 month ago / globenewswire.comAbsci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- 2 months ago / globenewswire.comAbsci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- 2 months ago / seekingalpha.comAbsci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Add to Watchlist
Select watchlists to add or remove ABSI